{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:32:15Z","timestamp":1775079135537,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T00:00:00Z","timestamp":1589068800000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejca.2019.03.020","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T12:40:23Z","timestamp":1557492023000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia"],"prefix":"10.1016","volume":"115","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natacha","family":"Maledon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalet Meral","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5405","key":"10.1016\/j.ejca.2019.03.020_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejca.2019.03.020_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2019.03.020_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","article-title":"Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study","volume":"95","author":"Mitra","year":"2012","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.ejca.2019.03.020_bib4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2019.03.020_bib5","first-page":"46","article-title":"Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995","volume":"99","year":"1999"},{"issue":"18","key":"10.1016\/j.ejca.2019.03.020_bib6","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/cncr.30767","article-title":"Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: the experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents","volume":"123","author":"Millot","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2019.03.020_bib7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejca.2019.03.020_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejca.2019.03.020_bib9","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2019.03.020_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2019.03.020_bib11","series-title":"ISCN 2009: international system of human cytogenetic nomenclature","author":"Shaffer","year":"2009"},{"issue":"1","key":"10.1016\/j.ejca.2019.03.020_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitor: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2019.03.020_bib13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2019.03.020_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"De la Fuente","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2019.03.020_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"10.1016\/j.ejca.2019.03.020_bib16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clml.2015.09.007","article-title":"Prognostic factors, response to treatment, and survival in patients with chronic myeloid leukemia in blast phase: a single-institution survey","volume":"15","author":"P\u00e9rez-Jacobo","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"11","key":"10.1016\/j.ejca.2019.03.020_bib17","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"Suppl1","key":"10.1016\/j.ejca.2019.03.020_bib18","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1182\/blood.V126.23.2789.2789","article-title":"Description and management of accelerated phase and blast crisis in 21 CML pediatric patients","volume":"126","author":"Meyran","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ejca.2019.03.020_bib19","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"1235","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2019.03.020_bib20","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, \u2018real-world\u2019 cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejca.2019.03.020_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hon.2416","article-title":"Interphase FISH for BCR-ABL1 rearrangement on neutrophils: a decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia","volume":"36","author":"Balducci","year":"2018","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2019.03.020_bib22","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2019.03.020_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","article-title":"The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600mg: the GIMENA CML Working Party experience after a 7-year follow-up","volume":"94","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ejca.2019.03.020_bib24","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/bmt.2014.146","article-title":"Allogeneic hematopoietic stem cell transplantation in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone","volume":"49","author":"Jiang","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.ejca.2019.03.020_bib25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MPH.0000000000000636","article-title":"Outcomes following bone marrow transplantation in children with accelerated phase or blast crisis chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"38","author":"Shulman","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.03.020_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2141.1998.00542.x","article-title":"Lymphoid blast crisis of chronic myeloid leukaemia is associated with distinct clinico-haematological features","volume":"100","author":"Cervantes","year":"1998","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2019.03.020_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(87)90754-6","article-title":"Chronic myelogenous leukemia in blast crisis","volume":"83","author":"Kantarjian","year":"1987","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.ejca.2019.03.020_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2019.03.020_bib29","article-title":"Pilot prospective phase II study of nilotinib combined with chemotherapy for myeloid blastic phase of chronic myeloid leukemia or acute myeloid leukemia with BCR\/ABL1","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:08Z","timestamp":1760732648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919302229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":29,"alternative-id":["S0959804919302229"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.03.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}